INTERIM REPORT FOR KANCERA AB (PUBL) Q4 2016. January 1st – December 31st 2016
THE PERIOD JANUARY – DECEMBER 2016 IN BRIEF
SIGNIFICANT EVENTS DURING THE FOURTH QUARTER
SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD
Kancera AB (publ) has presented new information showing
STATEMENT FROM THE CEO
Kancera has recently selected a contract research company for the upcoming clinical study in the Fractalkine project following a competitive selection process. In the next step the final negotiations of the agreement with that company are to be concluded, and in parallel the application to the relevant Medical Products Agency and the ethics committee for permission to start a clinical Phase I study is to be submitted. Thus, the Fractalkine project proceeds in accordance with the plans presented in the prospectus for the rights issue in May, 2016.
Furthermore, we have been able to show that the company’s Fractalkine antagonist KAND567 (formerly KAN0440567) effectively counteract pain caused by vincristine which is used to treat several forms of both hematological and solid tumors. The goal for the KAND567 treatment is to enable effective cancer treatment without dose-limiting pain as well as to prevent permanent nerve- and pain-complications after a successful treatment. Today there is no effective treatment for this type of nerve damage.
We have also been able to show that treatment with KAND567 prevents immune cell (monocyte) infiltration of nerves and spinal cord, which in turn prevents nerve damage and enhanced pain sensitivity. This effect pattern reflects the neuro-protective effect previously shown for KAND567 in a disease model for the autoimmune disease multiple sclerosis.
Overall, the findings suggest that KAND567 has the potential to significantly improve the treatment of cancer as well as autoimmune diseases.
We also see progress in other parts of the project portfolio exemplified by a new ROR inhibitor whose effect is maintained throughout the day opening up the possibility of more indications, that milestones for the Vinnova-supported HDAC6 project have been achieved, and that PFKFB3 inhibitors become more effective against cells upon activation of RAS which is one of the cancer driving genes most difficult to inhibit.
Moreover, in the final phase of the EU-funded anti-parasite project we can note that Kancera’s newly developed compounds, directed against the parasite's genome, show promising efficacy against infection caused by the parasite Trypanosoma cruzi. The parasite causes Chagas disease which affects approximately 8 million people today. With these results, Kancera reached the ambitious goals of the EU-project to develop a new class of compounds active in an animal model of one of the most difficult parasitic diseases affecting man.
CEO Kancera AB (publ)
THIS IS KANCERA
Kancera develops the basis for new therapeutics, starting with new treatment concepts and ending with the sale of a drug candidate to international pharmaceutical companies. Kancera is currently developing drugs for the treatment of leukemia and solid tumors, based on blocking survival signals in the cancer cell and on addressing cancer metabolism. Kancera’s operations are based in the Karolinska Institutet Science Park in Stockholm and the company employs around 15 people. Kancera shares are traded on NASDAQ First North and the number of shareholders were more than 7700 as of January 13th, 2017. FNCA is Kancera’s Certified Adviser. Professor Carl-Henrik Heldin, Professor Håkan Mellstedt, and MD PhD Charlotte Edenius are board members and Kancera´s scientific advisers.
In 2006, Pharmacia’s and Biovitrum’s unit for the development of drug candidates was spun-out to create iNovacia AB. In 2008, iNovacia started drug development in collaboration with the Karolinska Institute. In May 2010, Kancera AB was formed by scientists from Cancer Center Karolinska, iNovacia AB and a group of private investors through capital contributions and two drug projects focusing on cancer. NASDAQ OMX approved Kancera’s listing on First North with the first day of trading being February 25, 2011. In March 2013 Kancera acquired a complete drug development laboratory from its former subsidiary iNovacia AB and the drug development is since then performed within Kancera AB at the Karolinska Institutet Science Park, Stockholm.